Nasal Foralumab Led to Promising Immune Effects in Phase 1 Trial

Nasal Foralumab Led to Promising Immune Effects in Phase 1 Trial

295390

Nasal Foralumab Led to Promising Immune Effects in Phase 1 Trial

Nasally-administered foralumab, a potential treatment for neurodegenerative disorders such as progressive forms of multiple sclerosis (MS), appears safe and well-tolerated, and shows immune-modulating and anti-inflammatory effects in healthy volunteers, an updated analysis from a Phase 1 trial has found. “Nasal administration of Foralumab is a unique approach to treat patients with neurodegenerative diseases such as progressive MS, amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease,” Howard Weiner, MD, the Harvard Medical School neurology professor who reformulated…

You must be logged in to read/download the full post.